Press Release
nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B
January 28, 2026
Press Release
nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA 1001 for the Treatment of Chronic Hepatitis B
December 16, 2025
Resource
Establishment of assay limits for differential gene expression and DNA methylation to characterize specificity of epigenetic editing
November 10, 2025
AASLD Conference
Resource
Epigenetic editors targeting chronic Hepatitis B achieve HBV surface antigen loss with a single course of treatment in multiple HBV mouse models
November 7, 2025
AASLD Conference
Press Release
nChroma Bio Presents Preclinical Data Demonstrating Epigenetic Silencing Approach as a Potential Functional Cure for Chronic Hepatitis B at AASLD 2025
November 7, 2025
Press Release
nChroma Bio Abstracts Accepted for The Liver Meeting® 2025 of the American Association for the Study of Liver Diseases (AASLD)
October 7, 2025
Resource
Integrated epigenetic and genetic programming of primary human T cells
September 9, 2025
Nature Biotechnology
Resource
Efficient and Liver-Detargeted In Vivo Multiplex Gene Editing of Human Hematopoietic Stem and Progenitor Cells
May 14, 2025
ASGCT Conference
Resource
Engineered Virus-Like Particles with Minimal Viral Components for Improved Base Editing Efficiency In Vivo
May 14, 2025
ASGCT Conference
Resource
E4/K4 Coiled-Coils Improve Cargo Loading in Engineered Virus-like Particles
May 14, 2025
ASGCT Conference